Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Recordati Industria Chimica e Farmaceutica SpA
Pre-Tax Income
Recordati Industria Chimica e Farmaceutica SpA
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
|
Pre-Tax Income
€543.1m
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
|
Newron Pharmaceuticals SpA
SIX:NWRN
|
Pre-Tax Income
-€18.8m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Friulchem SpA
MIL:FCM
|
Pre-Tax Income
-€276.2k
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Shedir Pharma Srl Unipersonale
MIL:SHE
|
Pre-Tax Income
€8.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Recordati Industria Chimica e Farmaceutica SpA
Glance View
Nestled within the vibrant landscape of the Italian pharmaceutical industry, Recordati Industria Chimica e Farmaceutica SpA has carved a distinct identity over its nearly century-long journey. Founded in 1926 by Giovanni Recordati, the company has evolved from a small chemical laboratory into one of Europe's prominent players in pharmaceuticals. The heart of Recordati's operations lies in its robust portfolio, which spans pharmaceuticals, rare disease treatments, and consumer health products. With a commitment to innovation and diligent R&D efforts, Recordati continuously develops both proprietary drugs and generic medicines, ensuring a diverse revenue stream. Aiming to address crucial health challenges, the company has strategically expanded its rare disease segment, exploring niche markets with high unmet medical needs. Recordati's business model is a sophisticated blend of internal development, strategic acquisitions, and partnerships. The company's success largely hinges on its ability to identify and integrate complementary businesses, enhancing its global footprint. Through a network covering Western Europe, Central and Eastern Europe, as well as North America and emerging markets, Recordati not only distributes its own line of medications but also collaborates with other pharmaceutical entities to commercialize their products. This strategic expansion, coupled with a proactive approach to fostering market-specific adaptations, supports a steady flow of revenue. Revenue sustainability is further bolstered by a responsive supply chain and targeted marketing strategies that strengthen Recordati's competitive stance in the pharmaceutical sector worldwide.
See Also
What is Recordati Industria Chimica e Farmaceutica SpA's Pre-Tax Income?
Pre-Tax Income
543.1m
EUR
Based on the financial report for Sep 30, 2024, Recordati Industria Chimica e Farmaceutica SpA's Pre-Tax Income amounts to 543.1m EUR.
What is Recordati Industria Chimica e Farmaceutica SpA's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
10%
Over the last year, the Pre-Tax Income growth was 13%. The average annual Pre-Tax Income growth rates for Recordati Industria Chimica e Farmaceutica SpA have been 6% over the past three years , 5% over the past five years , and 10% over the past ten years .
You don't have any saved screeners yet